ArticleDiabetology international2025
Real-world use of finerenone in diabetic kidney disease: eGFR slope analysis with exploratory data on prior MRA use.
Article in Diabetology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Early laboratory trajectories and short-term tolerability after finerenone initiationin diabetic kidney disease: the multicenter FINE-TURK study.BMC nephrology · 2026Observational
- Real-world study of finerenone in patients with heart failure with preserved ejection fraction in Spain.BMC cardiovascular disorders · 2026Observational
- Finerenone in Asian Patients with Type 2 Diabetes Mellitus and Albuminuric Chronic Kidney Disease: From Evidence to Implementation.Diabetes & metabolism journal · 2026Review
- The appropriateness of finerenone initiation, dosing, and outcomes in diabetic kidney disease: data from real world practice.BMC nephrology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the post-SGLT2 inhibitor era, residual renal risk remains a major concern in diabetic kidney disease (DKD). Finerenone, a non-steroidal mineralocorticoid receptor antagonist (MRA), has shown cardiovascular and renal benefits in clinical trials. However, its effectiveness in patients previously treated with other MRAs remains unclear. We retrospectively analyzed 73 patients with DKD who were treated with finerenone at Shimane University Hospital between June 2022 and March 2024. The primary outcome was the change in estimated glomerular filtration rate (eGFR) slope before and after finerenone initiation. The mean eGFR slope significantly improved following finerenone initiation (-7.3 to -0.5 mL/min/1.73 m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.